Fig. 8.

A‐769662 treatment increases MMP in patient fibroblasts. (A) Relative mtDNA copy number from human primary fibroblast cells (2 controls; 2 patient cell lines bearing the Polγ homozygous mutations Y955C and V1106A, respectively) was measured before and after treatment with A‐769662 (100 μm) for 24 h. n = 6. Asterisks on untreated samples indicate the P‐value of the comparison with the untreated Control 1 cell line; the asterisk on the A‐769662‐treated Ctrl2 sample marks the comparison with the untreated Ctrl2. (B) The mitochondrial membrane potential (MMP) of human primary fibroblast cells treated or not with A‐769662 (100 μm) for 72 h was estimated by flow cytometry as described in Fig. 1L. Relative MMP is expressed as ΔTMRE/NAO. n = 4. Results were analyzed by unpaired t test; error bars in the graphs represent standard deviation. (n, number of biological replicates; ns, not significant; *P ≤ 0.05; ***P ≤ 0.001).